Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper
Allergy · 2026-11-20
DOI: 10.1111/all.70567 ↗At a glance
Journal article in Allergy, published online on 2026-11-20. Written by Sevim Bavbek and 11 co-authors. Institution: Faculty of Medicine, Department of Chest Diseases, Division of Immunology and Allergic Diseases, Ankara University, Ankara, Türkiye. 66 references. Funded by: European Academy of Allergy and Clinical Immunology.
Abstract (original language)
Histamine H2‐receptor antagonists (H2RAs) are widely used drugs which can induce immediate and delayed hypersensitivity reactions (HSRs) including anaphylaxis, urticaria, contact dermatitis, and severe cutaneous adverse reactions. The available evidence is limited by the fact that most data come from case reports and by the absence of large‐scale studies. Furthermore, the reported cases are mostly linked to ranitidine, which has been withdrawn from the global market. Consequently, the pathogenesis of these reactions is unclear, resulting in significant clinical challenges. Limited data suggest the usefulness of skin tests (STs) in patients with suspected HSRs to H2RA, but optimal STs concentrations have yet to be established. The same applies to drug provocation tests (DPTs) protocols, which are not standardized. Therefore, the authors recommend taking a step‐by‐step diagnostic approach. Clinicians are advised to establish non‐irritative STs concentrations by testing healthy control subjects. In patients with negative skin test results, supervised DPTs are recommended to confirm tolerance or identify safe alternatives. As cross‐reactivity among H2RAs is inconsistent, alternative H2RAs should only be selected following a complete allergological work‐up. Addressing these gaps is essential for the safe management of patients, particularly in the light of the recent global re‐licensing of reformulated H2RAs.
Subjects
Author keywords
Authors and institutions
- Faculty of Medicine, Department of Chest Diseases, Division of Immunology and Allergic Diseases, Ankara University, Ankara, Türkiye.
- Imperial College Healthcare NHS Trust, Chest and Allergy Clinic, London, UK.
- İzmir Faculty of Medicine, Department of Chest Diseases, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital, Division of Allergy and Immunology, University of Health Sciences Türkiye, İzmir, Türkiy…
- Division of Dermatology, Allergy Outpatient Clinic, Azienda Sanitaria Universitaria Integrata del Trentino (ASUIT)- Trento Hospital, Trento, Italy.
- Faculty of Medicine, University Children's Hospital, University of Belgrade, Belgrade, Serbia.
- Hôpital Tenon, Département de Dermatologie et Allergologie, Sorbonne Université, INSERM, Institut Pierre Louis D'epidémiologie et de Santé Publique, AP-HP, Paris, France.
ORCID profiles: Sevim Bavbek, Alla Nakonechna, Seçil Kepil Özdemir, Carla Lombardo, Marina Atanasković-Marković, Annick Barbaud, Knut Brockow, Patrizia Bonadonna, Jose Julio Laguna, Giorgia Marta, Mauro Pagani, Maria Jose Torres
Funding
- European Academy of Allergy and Clinical Immunology
Cite
APA
Bavbek, S., Nakonechna, A., Özdemir, S. K., Lombardo, C., Atanasković-Marković, M., Barbaud, A., Brockow, K., Bonadonna, P., Laguna, J. J., Marta, G., Pagani, M., & Torres, M. J. (2026). Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper. Allergy. https://doi.org/10.1111/all.70567
Vancouver
Bavbek S, Nakonechna A, Özdemir SK, Lombardo C, Atanasković-Marković M, Barbaud A, et al. Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper. Allergy. 2026. doi:10.1111/all.70567
BibTeX
@article{Bavbek2026,
author = {Bavbek, Sevim and Nakonechna, Alla and Özdemir, Seçil Kepil and Lombardo, Carla and Atanasković-Marković, Marina and Barbaud, Annick and Brockow, Knut and Bonadonna, Patrizia and Laguna, Jose Julio and Marta, Giorgia and Pagani, Mauro and Torres, Maria Jose},
title = {Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper},
journal = {Allergy},
year = {2026},
doi = {10.1111/all.70567}
}
EUVIMED